A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases.

Front Immunol · 2024 · PMC11670205 · PMID 39726595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

TAVO101 showed a trend of slightly better efficacy (albeit not statistically significant) in neutralizing TSLP activity than tezepelumab in these assays.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.